EGFR and head and neck squamous cell carcinoma: When cultured HNSCC cells were treated with cetuximab, a monoclonal antibody against EGFR or gefitinib, a specific inhibitor of EGFR, CXCL14 expression was increased in HSC-2, HSC-3, and HSC-4 cells, but not in YCU-H891 cells.